Objective: We conducted a phase II trial to evaluate the activity of oral letrozole in women with relapsed or recurrent epithelial ovarian cancer. Methods: Twenty-seven patients were treated with letrozole at a dose of 2.5 mg once a day. Patients with measurable or evaluable disease (n = 21) and those with only increasing CA 125 serum levels (n = 6) were eligible. Paraffin-fixed histological sections from tumor specimens resected at the initial laparotomy were assessed for the presence of estrogen, and progesterone receptors. Results: Among the 21 patients with measurable or evaluable disease who were evaluated for response by WHO criteria, we observed one complete and two partial responses for an objective response rate of 15%. Using criteria for CA 125 response we obtained a marker response in 4 of 27 patients (15%), and the marker remained stable in 5 additional patients (18%). Letrozole treatment was generally well tolerated. No correlation was observed between tumor marker response or stabilization and either estrogen or progesterone receptor expression. Conclusion: The results of our study suggest that the aromatase inhibitor letrozole is an agent with some activity and limited toxicity for relapsed ovarian cancer. As we could not find any association between response and hormonal receptor expression, the underlying mechanisms of letrozole action have to be elucidated.

Keywords:
Letrozole, Ovarian cancer, Hormonal therapy
1.
Ozols R, Rubin SC, Thomas G, Robboy S: Epithelial ovarian cancer; in Huskins WM, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, ed 2. Philadelphia, Lippincott-Raven, 1997, pp 919–986.
2.
Mc Guire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III or IV ovarian cancer. N Engl J Med 1996;334:1–6.
3.
Neijt JP: New therapy for ovarian cancer. N Engl J Med 1996;334:50–51.
4.
Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999;18:356.
5.
Du Bois A, Neijt JP, Thigpen JT: First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer: A new standard of care? Ann Oncol 1999;10(suppl 1):S35–S41.
6.
Du Bois A, Lueck HJ, Meier W, et al: Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial. Proc Am Soc Clin Oncol 1999;18:356.
7.
Aravantinos G, Fountzilas G, Kosmidis P, et al: Alternating carboplatin and cisplatin plus paclitaxel for first-line treatment of advanced ovarian cancer (AOC): Updated results of a phase III Hellenic Cooperative Oncology Group study. Proc Am Soc Clin Oncol 2000;19:389.
8.
Ozols RF: Treatment of recurrent ovarian cancer: Increasing option-recurrent results. J Clin Oncol 1997;15:2177–2180.
9.
Sabbatini P, Sprongs D: Salvage therapy for ovarian cancer. Oncology 1998;12:383–344.
10.
Bhatnagar AS, Hausler A, Schieweck K: Inhibition of aromatase in vitro and in vivo by aromatase inhibitor. J Enzyme Inhib 1990;4:179–186.
11.
Smith IE: Pivotal trials of letrozole: A new aromatase inhibitor. Oncology 1998;12(suppl 5):41–44.
12.
Miller AB, Hogestraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207–214.
13.
Rustin GJS, Nelstrop AE, Bentzen SM, Bond SJ, McClean P: Selection of active drugs for ovarian cancer based on CA 125 and standard response rates in phase II trials. J Clin Oncol 2000;18:1733–1739.
14.
Meyer T, Rustin GJS: Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535–1538.
15.
Kaplan E, Meier F: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;58:457–481.
16.
Markman M, Hoskins W: Response to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated populations. J Clin Oncol 1992;10:513–514.
17.
Makar AP: Hormone therapy in epithelial ovarian cancer. Endocrine-Related Cancer 2000;7:85–93.
18.
Wu MI, Whittemore AS, Paffenbarger JR, et al: Personal and environmental characteristics related to epithelial ovarian cancer in reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988;6:1216–1227.
19.
Gwin ML, Lee N, Rhodes PH, Layde PM, Rubin G: Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989;43:559–568.
20.
Slotman BJ, Rao BR: Ovarian cancer (review): Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res 1988;8:417–434.
21.
Simons WE, Albrecht M, Hansel M, Dietl M, Holzel F: Cell line derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones. J Nat Cancer Inst 1983;70:839–845.
22.
Miller WR, Langdon SP: Steroid hormones and cancer. II. Lessons form experimental system. Eur J Surg Oncol 1997;23:72–83.
23.
Langdon SP, Hawkes MM, Lawrie SS, et al: Estrogen receptor expression and the effects of tamoxifen on the growth of human carcinoma cell lines. Br J Cancer 1990;62:213–216.
24.
Langdon SP, Crew AJ, Ritchie AA, et al: Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by oestrogens in vitro and in vivo. Eur J Cancer 1994;30A:682–686.
25.
Peterson CM, Zimmiski S: A long-acting gonadotropin releasing hormone agonist inhibits the growth of a human ovarian epithelial carcinoma (BG-1) heterotransplanted in the nude mouse. Obstet Gynecol 1990;76:264–267.
26.
Trope C, Johnsson JE, Sigurdsson K, Simonse E: High-dose medroxyprogesterone acetate for the treatment of advanced ovarian cancer. Cancer Treat Rev 1982;66:1441–1443.
27.
Thigpen JT, Vance RB, Balducci L, Khansur T: New drugs and experimental approaches in ovarian cancer treatment. Semin Oncol 1984;11:314–326.
28.
Veenhof CH, van der Burg ME, Nooy M, et al: Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur J Cancer 1994;30:697–698.
29.
Van der Vange N, Greggi S, Burger W, Kenemans P, Vermoken JB: Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995;34:813–820.
30.
Parmar H, Philips RH, Rustin G, Lighman SL, Shally AV: Therapy of advanced ovarian with d-Trp-6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother 1988;42:531–538.
31.
Adelson MD, Reece MT: Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors. Clin Obstet Gynecol 1993;36:690–700.
32.
Marinaccio M, D’Addario VD, Serrati A, Pinto V, Gagnazzo G: Leurpolide acetate as a salvage therapy in relapsed epithelial ovarian cancer. Eur J Clin Oncol 1996;17:286–288.
33.
Williams CJ: Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2000;2:CD001034.
34.
Kavanagh JJ, Wharton JT, Roberts WS: Androgen therapy in the treatment of refractory epithelial ovarian cancer. Cancer Treat Report 1987;71:537–538.
35.
Vassilomanolakis M, Koumakis G, Barbounis V, Hajichristou H, Tsousis S, Efremidis A: A phase II study of flutamide in ovarian cancer. Oncology 1997;54:199–202.
36.
Rothsschild N, Gray R, Smith L, Matelski H, Ahlagren J: Phase II study of aminoglutethimide in advanced ovarian cancer. Proc Am Soc Clin Oncol 1987;6:115.
37.
Ahlgren JD, Ellison NM, Gottlieb RJ, et al: Hormonal palliation of chemo-resistant ovarian cancer: three consecutive phase III trials of the mid-Atlantic oncology program. J Clin Oncol 1993;11:1957–1968.
38.
Bowman A, Gabra H, Langdon SP, et al: CA 125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subroup. Clin Cancer Res 2002;8:2233–2239.
39.
Shirley DR, Kavanagh JJ, Gerhsenson DM, Freedman RS, Copeland LJ, Jones LA: Tamoxifen therapy for epithelial ovarian cancer. Obstet Gynecol 1985;66:575–578.
40.
Beecham J, Blessing J, Creasman W, Hatch K: The role of tamoxifen as second line therapy in advanced ovarian cancers evaluated for receptors status and tumor grade. Proc Int Gynecol Cancer Soc 1987;1:117.
41.
Weiner SA, Alberts DS, Surwit EA, Davis J, Grosso D: Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol 1987;27:208–213.
42.
Schwartz PE, Chambers JT, Kohorn EL et al: Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. Cancer 1989;63:1074–1078.
43.
Rose PG, Reale FR, Longcope C, Hunter RE: Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. Obstet Gynecol 1990;76:258–263.
44.
Hatch KD, Beechan JB, Blessing JA, Creasman WT: Responsiveness of patients with relapsed ovarian cancer to tamoxifen. Cancer 1991;68:269–269.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.